MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program
The company will engage in BIO One-on-One Partnering™ meetings as it advances Phase 1 for Ketamir-2, prepares Phase IIa study in neuropathic pain, and finalizes filings for SKNY acquisition.
MIAMI, FL / ACCESS Newswire / May 28, 2025 / MIRA Pharmaceuticals, Inc. (Nasdaq:MIRA) ('MIRA' or the 'Company'), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced that it will participate in the BIO International Convention 2025, taking place in Boston, MA from June 16-19, 2025. The Company has a full schedule of BIO One-on-One Partnering™ meetings planned as it explores potential licensing, strategic partnerships, and M&A opportunities.
The Company's lead candidate, Ketamir-2, a next-generation oral ketamine analog, is currently undergoing a Phase 1 clinical trial. With the second dosing cohort completed, the Company is now preparing to initiate the third cohort. Building on this momentum, MIRA anticipates initiating a Phase IIa study in neuropathic pain before the end of the year, advancing the development of what the Company believes could be a safe, effective non-opioid alternative for chronic pain management.
In addition, MIRA is advancing a series of preclinical studies with Ketamir-2, including models evaluating its potential in PTSD, as well as a topical formulation aimed at treating localized inflammatory pain. The Company is also finalizing regulatory filings related to its acquisition of SKNY Pharmaceuticals, Inc. ('SKNY'), with submission to the U.S. Securities and Exchange Commission (SEC) expected in the coming weeks. SKNY-1, SKNY's primary pharmaceutical candidate, is being developed as an oral therapeutic targeting smoking cessation and obesity, with activity at CB1, CB2, and MAO-B receptors.
'Our pipeline is advancing on all fronts, and we are focused on turning this scientific momentum into long-term value for patients and shareholders,' said Erez Aminov, Chief Executive Officer of MIRA. 'As we move closer to initiating Phase IIa and completing the SKNY transaction, we're actively exploring strategic opportunities to accelerate growth, including licensing and partnerships-especially in areas like chronic pain where non-opioid alternatives like Ketamir-2 are urgently needed.'
Dr. Angel, Chief Scientific Advisor at MIRA, added:
'We believe Ketamir-2 is paving the way for a new class of non-opioid therapies. The science is compelling, and the progress we have made is truly exciting. I look forward to sharing the depth of our work and the promising data we've generated with potential partners and investors.'
Cautionary Note Regarding Forward-Looking Statements
This press release and the statements of MIRA's management related thereto contain 'forward-looking statements,' which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will,' and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA's potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and other SEC filings, which are on file with the SEC at www.sec.gov and MIRA's website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Contact Information
Helga Moya
[email protected]
(786) 432-9792
SOURCE: MIRA Pharmaceuticals
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
36 minutes ago
- Associated Press
NBA's talks about new league in Europe are continuing, though the process remains in early stages
OKLAHOMA CITY (AP) — The NBA's talks with FIBA and other entities about the process of adding a new league in Europe are continuing, Commissioner Adam Silver said, though he noted that it may take at least a couple more years to turn the ideas into reality. Silver spoke at a league event to unveil a refurbished Boys & Girls Club in Oklahoma City on Friday — an off day for the NBA Finals — and said it's difficult to put a specific timeline on the Europe plans. 'I will say it's measured in years, not months,' Silver said. 'So, we're at least a couple years away from launching. It would be an enormous undertaking. And while we want to move forward at a deliberate pace, we also want to make sure that we're consulting with all the appropriate stakeholders, meaning the existing league, its teams, European players, media companies, marketing partners. There's a lot of work to be done.' Silver and FIBA secretary general Andreas Zagklis announced in March that the league and the game's governing body are finally taking long-awaited steps to form a new league, with an initial target of 16 teams. It had been talked about for years, and decades even on some levels. And since the NBA and FIBA went public with their idea to move forward, talks have gotten more constructive, Silver said. Silver said the NBA has been talking directly with the EuroLeague and with some member clubs about a partnership. It's his preference that the NBA work with the existing league on some level, though it's still too early to say exactly what that means. 'Either way, we continue to feel there are an enormous number of underserved basketball fans in Europe and that there's a strong opportunity to have another league styled after the NBA,' Silver said. About one in every six current NBA players hails from Europe, including Denver's Nikola Jokic (Serbia) and Milwaukee's Giannis Antetokounmpo (Greece) — who have combined for five of the last seven MVP awards — along with the Los Angeles Lakers' Luka Doncic (Slovenia) and San Antonio's Victor Wembanyama (France). The NBA's board of governors will talk more about next steps with the European plans in July at their scheduled meeting in Las Vegas, Silver said. It's possible that the European venture could be unveiled in some way — or possibly start — around the 2028 Los Angeles Olympics, just given how much attention will be on international basketball at that time. 'That might be a good launching pad for an announcement around a new competition,' Silver said. Some of the cities that are expected to have interest in being part of the new venture include London, Manchester, Rome and Munich. There will be others, of course. 'We haven't had direct conversations yet,' Silver said. 'But there have been several organizations that have come forward and said they would be interested and potential owners in operating in those major markets in Europe.' ___ AP NBA:
TechCrunch
39 minutes ago
- TechCrunch
Trump fast-tracks supersonic travel, amid spate of flight-related executive orders
In Brief President Donald Trump signed an executive order Friday that directs the Federal Aviation Administration to lift the 52-year ban on supersonic flight over U.S. soil, marking a major policy shift that occurred just weeks after lawmakers introduced bipartisan legislation with the same aim. The order instructs the FAA to end the overland supersonic ban and create noise-based certification standards, allowing faster-than-sound travel as long as no audible sonic boom reaches the ground. 'The reality is that Americans should be able to fly from New York to LA in under four hours,' Michael Kratsios, the director of the White House Office of Science and Technology Policy, told reporters Friday. The move could help accelerate commercial supersonic flight development, including efforts by Boom Supersonic. In January, Boom's XB-1 demonstrator became the first privately developed civil aircraft to break the sound barrier over the continental U.S. Asked for comment Friday, Boom CEO Blake Scholl wrote 'Booooom!' in an email to TechCrunch. Added Scholl, 'The sound barrier was never physical — it was regulatory. With supersonic legalized, the return of supersonic passenger air travel is just a matter of time.' Trump also signed two other future-of-flight executive orders Friday: one to speed up drone commercialization and electric vertical takeoff vehicle development, and another to establish a federal task force on drone flight restrictions.
Forbes
42 minutes ago
- Forbes
Republicans Like Health Savings Accounts
Should the government allow HSAs to cover gym memberships? Health Savings Accounts (HSAs) are a popular and important way many people pay for medical expenses. They are also a great way to save—better, for example, than an IRA or a 401(k) plan. Because of various quirks in the law, HSAs are not available to a large number of people—including people on Medicaid or Medicare and most people who buy their own insurance in the (Obamacare) exchanges. Under the reconciliation bill just passed in the House of Representatives, more people will have access to these accounts and there will be new opportunities to use them. Currently, individuals and their employers can make tax-free deposits to HSAs, provided the individual is also covered by third-party health insurance with a high deductible. Money can accumulate and grow tax-free. After age 65, the money can be withdrawn for non-health expenses without penalty, but it is subject to normal income taxes. As of 2023, there were 37.4 million accounts with $46.4 billion in assets. Industry experts think the House bill will lead to an additional 20 million people with an HSA. Here is a summary of the hits and misses in the Republican bill, as it faces a vote by the Senate. The Good. By far the best feature of the bill is a provision making all bronze and catastrophic insurance plans offered through the (Obamacare) exchanges automatically eligible for an HSA account. This is likely the main reason why the number of HSA accounts is likely to soar. Another provision would allow the use of HSAs to pay monthly fees for direct primary care (DPC). This used to be called 'concierge care' and in the past it was available only to the rich. But the price has come way down. Atlas MD in Wichita, for example, charges $50 a month for a mother and $10 for a child. In return, the family has 24/7 access to a physician's practice that provides all primary care. Often, the family has the doctor's personal phone number. DPC has become increasingly popular, and employers often pay the monthly fee for their employees. Under current law, however, the employer cannot put funds in an HSA account, let the employee choose a DPC doctor and pay that doctor from the account. The House bill will create that opportunity. According to the Congressional Budget Office (CBO), the ten-year cost of all of the HSA changes combined is almost $44 billion. Yet the cost of the two best provisions is less than $6 billion. More on that below. The Questionable. The bill allows annual withdrawals of $500 (individuals) or $1,000 (couples) for gym memberships and other physical activities. (No sailing or golfing expenses, however.) The problem is that these are not medical expenses. If we are going to allow gym memberships, why not hundreds of other nonmedical expenses – including sailing and golfing? The CBO says the cost of this provision is $10 billion. The bill also doubles the annual HSA contribution that is allowable for individuals with incomes up to $75,000 and couples who earn up to $150,000. The problem here is that only about one in ten account holders are contributing the maximum allowable right now. At a cost of more than $8 billion this is an expensive change that will only affect a small part of the market. Instead of these questionable measures, the Senate should consider making all Obamacare silver plans (the most popular choice) automatically eligible for an HSA. Missed opportunities. While the House should be congratulated for making many desirable improvements in the HSA law, it unfortunately failed to correct a fundamental flaw: an inflexible across-the-board deductible. Common sense would suggest that different medical expenses need different deductibles. The biggest problem with chronic illness, for example, is noncompliance with a drug regimen. That is why some Medicare Advantage plans make maintenance drugs for chronic patients (such as insulin for diabetics) available for free or at very low cost. In the first Trump administration, an IRS ruling waived the deductible requirement for 14 specific services and medications that serve as treatments for such conditions as diabetes, asthma, heart disease, and depression. This was an executive branch decision to modify existing legislation, however. To make it permanent, Congress needs to codify it. Ideally, Congress should remove the deductible requirement altogether and let the role of deductibles be determined in the marketplace. One way to think about the combination of allowing gym memberships and failing to address the deductible issue is to see that the House risks being accused of creating benefits for the healthy while ignoring the sick. Another missed opportunity was the failure of House Republicans to give 80 million Medicaid enrollees access to what I will call a Roth HSA. Private companies managing Medicaid (or the state itself) should be able to make deposits to an account that would cover, say, all primary care. Enrollees could use the money for health care during an insurance year. Afterward, they could withdraw any unspent funds for any purpose. If there were no taxes or penalties on non-medical withdrawals, health care and non-health care would trade against each other on a level playing field under the tax law. People wouldn't spend a dollar on health care unless they got a dollar's worth of value. An early study by the RAND Corporation suggests that these accounts would reduce Medicaid spending by 30 percent. Aside from payments for the disabled and nursing home care, if Medicaid spending could be reduced by 30 percent, the savings would amount to almost $1 trillion over ten years. This saving would be shared by the beneficiaries and the taxpayers who fund Medicaid.
